Impact Biomedical (IBO) Change in Accured Expenses (2022 - 2026)

Impact Biomedical (IBO) has 5 years of Change in Accured Expenses data on file, last reported at $16000.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 33.33% year-over-year to $16000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2000.0 (down 98.75% YoY) and the FY2025 annual result came in at -$2000.0, up 94.29% from the prior year.
• Change in Accured Expenses improved to $16000.0 in Q1 2026, from -$142000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $224000.0 in Q4 2023 to a low of -$183000.0 in Q1 2024.
• A 5-year average of $13600.0 and a median of $14000.0 in 2024 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 583.33% in 2024, down 1307.69% in 2024.
• Tracing IBO's Change in Accured Expenses over 5 years: stood at $51000.0 in 2022, then surged by 339.22% to $224000.0 in 2023, then plunged by 58.48% to $93000.0 in 2024, then plunged by 252.69% to -$142000.0 in 2025, then surged by 111.27% to $16000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $16000.0 (Q1 2026), -$142000.0 (Q4 2025), and $69000.0 (Q3 2025), per Business Quant data.